Valuation: Novavax, Inc.

Market Cap 1.67B 1.45B 1.37B 1.25B 2.34B 160B 2.35B 16.45B 6.35B 81.35B 6.26B 6.13B 262B P/E 2026 *
-16.2x
P/E 2027 * -45.1x
Enterprise Value 1.89B 1.65B 1.55B 1.41B 2.64B 181B 2.65B 18.61B 7.18B 92.04B 7.09B 6.93B 296B EV / Sales 2026 *
5.06x
EV / Sales 2027 * 7.4x
Free-Float
93.03%
Yield 2026 *
-
Yield 2027 * -
1 day+1.10%
1 week+7.32%
Current month+7.90%
1 month+27.49%
3 months+10.73%
6 months+1.00%
Current year+50.45%
1 week 9.14
Extreme 9.135
10.38
1 month 8.02
Extreme 8.02
10.75
Current year 6.76
Extreme 6.76
11.97
1 year 6.2
Extreme 6.2
11.97
3 years 3.53
Extreme 3.5324
23.86
5 years 3.53
Extreme 3.5324
260.69
10 years 3.53
Extreme 3.5324
331.68
Manager TitleAgeSince
Chief Executive Officer 59 23/01/2023
Director of Finance/CFO 60 16/08/2021
Chief Tech/Sci/R&D Officer - 01/01/2022
Director TitleAgeSince
Director/Board Member 73 06/08/2010
Director/Board Member 66 01/11/2018
Director/Board Member 60 16/06/2020
Date Insider Type Main position Quantity % Market Cap. Importance
20/6/26 Exercice

Director

37,760 0.0230%
18/6/26 Free

Director

35,450 0.0216%
25/4/26 Exercice

Director

19,040 0.0117%
Change 5-day change 1-year change 3-year change Capi.($)
+1.10%+7.32%+18.52%+36.44% 1.67B
+0.11%+2.71%+0.33%+28.59% 46.28B
-1.12%+1.78%+40.07%+27.26% 43.85B
-3.04%-6.29%+322.27%+517.36% 40.93B
-0.74%+1.25%+2.32%+67.94% 39.9B
-0.50%+0.67%+11.79%+40.51% 29.5B
-0.46%+4.22%+21.99%+124.21% 17.09B
-0.97%-10.17% - - 15.55B
-0.57%+8.12%+22.15%+38.93% 15.22B
-3.14%+31.91%-10.60% - 14.05B
Average -0.78%+2.79%+47.65%+110.15% 26.4B
Weighted average by Cap. -1.01%+1.01%+64.38%+129.56%

Financials

2026 *2027 *
Net sales 373M 325M 307M 279M 522M 35.79B 525M 3.68B 1.42B 18.19B 1.4B 1.37B 58.54B 266M 232M 219M 199M 373M 25.54B 374M 2.63B 1.01B 12.99B 1B 978M 41.78B
Net income -108M -93.78M -88.55M -80.41M -151M -10.32B -151M -1.06B -409M -5.25B -404M -395M -16.88B -37.93M -33.07M -31.23M -28.36M -53.13M -3.64B -53.35M -374M -144M -1.85B -142M -139M -5.95B
Net Debt 219M 191M 180M 164M 307M 21.01B 308M 2.16B 834M 10.68B 823M 804M 34.38B 303M 264M 250M 227M 425M 29.09B 427M 2.99B 1.15B 14.79B 1.14B 1.11B 47.6B
Logo Novavax, Inc.
Novavax, Inc. is a biotechnology company. It is focused on addressing global health challenges through its vaccines and its proven technology platform, including protein-based nanoparticles and its Matrix-M adjuvant. Matrix-M can be used to create vaccines for a variety of diseases to help tackle some of the pressing health challenges. Its proprietary Matrix-M adjuvant, when added to vaccines, has been shown to help induce a stronger and longer-lasting immune response. Its recombinant protein-based nanoparticle technology has been shown to be highly immunogenetic. Its technology platform is used in its authorized COVID-19 vaccine and the R21/Matrix-M adjuvant malaria vaccine. Its late-stage programs include a COVID-19-Influenzavaccine candidate, and an influenza vaccine candidate. R21/Matrix-M adjuvant malaria vaccine, a malaria vaccine developed by its partner. It provides Matrix-M adjuvant for use in various programs in preclinical and clinical stage, and preclinical investigations.
Employees
749
Date Price Change Volume
18/09/26 USD 10.11 +1.10% 11,145,562
17/09/26 USD 10.00 +6.95% 8,876,144
16/09/26 USD 9.350 +1.30% 2,849,467
15/09/26 USD 9.230 -3.75% 3,331,569
14/09/26 USD 9.590 +1.80% 3,366,869
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
BB
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
9
Last Close Price
10.11USD
Average target price
14.00USD
Spread / Average Target
+38.50%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. NVAX Stock
LAST HOURS | 40% Discount: The Best Subscriber-Only Tools to Unlock Hidden Opportunities!
d
:
:
SEIZE THE OFFER!